ASBP vs CRBP vs YCBD vs XXII vs ATAI

For growth investors, 22nd Century Group, Inc.

(XXII) is the stronger pick with 48. 1% revenue growth year-over-year, versus -1. 9% for Atai Beckley N. V (ATAI). Analysts rate Corbus Pharmaceuticals Holdings, Inc. (CRBP) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corbus Pharmaceuticals Holdings, Inc.

(CRBP) delivered a total return of -78. 0%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: ATAI returned -47. 7% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), cbdMD, Inc.

(YCBD) is the lower-risk stock at 0. 66β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 163% more volatile than YCBD relative to the S&P 500. On balance sheet safety, Corbus Pharmaceuticals Holdings, Inc. (CRBP) carries a lower debt/equity ratio of 1% versus 108% for cbdMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), 22nd Century Group, Inc.

(XXII) is pulling ahead at 48. 1% versus -1. 9% for Atai Beckley N. V (ATAI). On earnings-per-share growth, the picture is similar: 22nd Century Group, Inc. grew EPS 99. 9% year-over-year, compared to -272. 0% for Atai Beckley N. V. Over a 3-year CAGR, YCBD leads at -18. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corbus Pharmaceuticals Holdings, Inc.

(CRBP) is the more profitable company, earning 0. 0% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRBP leads at 0. 0% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, XXII (100.

0% yield) pays a dividend. ASBP, CRBP, YCBD, ATAI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, cbdMD, Inc.

(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, ASBP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ASBP (Healthcare) and CRBP (Healthcare) and YCBD (Healthcare) and XXII (Consumer Defensive) and ATAI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ASBP is a small-cap quality compounder stock; CRBP is a small-cap quality compounder stock; YCBD is a small-cap quality compounder stock; XXII is a small-cap high-growth stock; ATAI is a small-cap quality compounder stock. XXII pays a dividend while ASBP, CRBP, YCBD, ATAI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.